Procyon Corp PCYN
We take great care to ensure that the data presented and summarized in this overview for PROCYON CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PCYN
Top Purchases
Top Sells
About PCYN
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States. The company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. It also provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. In addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, home health agencies, physicians, and health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores. The company was incorporated in 1987 and is based in Clearwater, Florida.
Insider Transactions at PCYN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 31
2024
|
Joseph Raymond Treshler Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,440
+50.0%
|
$0
$0.25 P/Share
|
Jul 31
2024
|
Monica Mc Cullough Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+50.0%
|
$0
$0.25 P/Share
|
Jul 31
2024
|
Steven Mc Comas Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,600
+50.0%
|
$0
$0.25 P/Share
|
Jun 26
2024
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
40,000
-2.82%
|
$0
$0.18 P/Share
|
Jun 25
2024
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
40,000
-2.74%
|
$0
$0.19 P/Share
|
Jul 31
2023
|
Steven Mc Comas Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,600
+50.0%
|
$0
$0.25 P/Share
|
Jul 31
2023
|
Monica Mc Cullough Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,200
+50.0%
|
$0
$0.25 P/Share
|
Jul 31
2023
|
Joseph Raymond Treshler Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
$0
$0.25 P/Share
|
Mar 31
2022
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
40,000
-2.67%
|
$0
$0.38 P/Share
|
Feb 07
2022
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
15,000
-0.99%
|
$0
$0.35 P/Share
|
Dec 06
2021
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
25,000
-1.62%
|
$0
$0.32 P/Share
|
Mar 22
2021
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
15,000
-0.96%
|
$0
$0.6 P/Share
|
Oct 08
2020
|
Foundation Speer |
SELL
Open market or private sale
|
Direct |
10,000
-0.64%
|
$0
$0.22 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 20.2K shares |
---|
Open market or private sale | 80K shares |
---|